Top Growth Trends in the Adalimumab, Infliximab and Etanercept Biosimilars Market: Key Insights and Opportunities for 2025-2034
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What key factors are powering the surge in the adalimumab, infliximab and etanercept biosimilars market right now?
In recent years, there’s been a significant expansion in the market size for biosimilars of adalimumab, infliximab, and etanercept. The market is projected to propel from a value of $4.37 billion in 2024 to an estimated worth of $4.98 billion in 2025, showing a robust compound annual growth rate (CAGR) of 14.1%. Factors such as heightened healthcare spending, infrastructural modifications, government strategies, and escalating healthcare costs contributed to the historical period’s growth.
How fast Is the adalimumab, infliximab and etanercept biosimilars market expected to grow, and what’s its future value?
The market for biosimilars of adalimumab, infliximab, and etanercept is predicted to see notable expansion in the approaching years. By 2029, it’s forecasted to inflate to $7.44 billion, with a compound annual growth rate (CAGR) of 10.5%. This escalation in the projected years can be tied to factors such as elevated healthcare spending, a rising aged populace, and enhanced healthcare accessibility which propels the market’s expansion. Predominant directions in the forecasted era include the concentration on the introduction of new products, emphasis on mergers and takeovers, focusing on crafting strategic collaborations, and the intent to augment investments.
Get your adalimumab, infliximab and etanercept biosimilars market report here!
What are the leading drivers of growth in the adalimumab, infliximab and etanercept biosimilars market?
The adalimumab, infliximab, and etanercept biosimilars market is opened up by the patent expiration of branded drugs. For example, after the patent of the branded drug Remicade expired, the FDA in the United States sanctioned the use of Inflectra, a product developed by Hospira, a Pfizer Inc. company, for treating various autoimmune diseases such as rheumatoid arthritis, adult ulcerative colitis, and plaque psoriasis. Similarly, following the patent expiry for Amgen’s Enbrel in the EU, the European Commission approved the use of Benepali, a biosimilar of Enbrel. With the expiration of Humira’s patent, its biosimilars entered the market. The FDA has recently given the nod to Hulio, the sixth biosimilar of Humira. Therefore, the end of patents for branded biologic drugs like Humira, Enbrel, and Remicade will boost demand in the adalimumab, infliximab, and etanercept biosimilars market.
What are the key segments defining the adalimumab, infliximab and etanercept biosimilars market?
The adalimumab, infliximab and etanercept biosimilars market covered in this report is segmented –
1) By Product: Adalimumab Biosimilars, Infliximab Biosimilars, Cipleumab
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By Application: Crohn’s Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis, Other Applications
Subsegments:
1) By Adalimumab Biosimilars: Amjevita (Amgen), Hyrimoz (Sandoz), Cyltezo (Boehringer Ingelheim), Others
2) By Infliximab Biosimilars: Inflectra (Pfizer), Remsima (Celltrion), Ixifi (Pfizer), Others
3) By Cipleumab: Cipleumab Biosimilars, Other Biosimilars in Development
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3473&type=smp
Who are the key players steering the development of the adalimumab, infliximab and etanercept biosimilars market?
Major companies operating in the adalimumab, infliximab and etanercept biosimilars market include Biogen, Novartis (Sandoz), Pfizer, Amgen, Celltrion, Samsung Bioepis (Samsung Biologics), Hetero Drugs Limited, Fresenius Kabi AG, Boehringer Ingelheim, Biocon, Zydus Lifesciences Limited, Reliance Life Sciences, Torrent Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd, Cipla Limited, Zhejiang Hisun Pharmaceutical Co. Ltd, Bio-Thera Solutions, Ltd, Innovent Biologics (Suzhou) Co. Ltd, Janssen Biologics BV, Shanghai CP Guojian Pharmaceutical Co. Ltd, Sansheng Guojian, Shanghai Junshi Biosciences Co. Ltd, Mabwell Bioscience Co. Ltd, LG Chem, Nippon Kayaku, Mochida Pharmaceutical Co. Ltd, mAbxience, Allergan, Microgen, Geropharm, Valenta, NovaMedica Veropharm, Biocad, Roche, Bristol-Myers Squibb, Celon Pharma, SynBio, Ache, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, Mylan, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty) Ltd
What emerging trends are influencing the growth of the adalimumab, infliximab and etanercept biosimilars market?
Top-tier companies in the adalimumab, infliximab, and etanercept biosimilars market are centering their efforts on creating groundbreaking products such as citrate-free adalimumab, to deliver trustworthy services to consumers. Defined as a variation of the biopharmaceutical medication adalimumab that excludes citrate, citrate-free adalimumab is gaining attention. For instance, Fresenius Kabi, a medicament and technology provider for infusion, transfusion, and clinical nutrition based in Germany, proclaimed the FDA’s approval for the biosimilar Idacio (adalimumab) in December 2022. This approval is intended for the management of chronic autoimmune disorders, compatible with all approved uses of the reference product. This biosimilar was crafted using sophisticated analytical techniques for the treatment of an array of chronic diseases.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3473
Which regions are most influential in expanding the adalimumab, infliximab and etanercept biosimilars market?
North America was the largest region in the adalimumab, infliximab, and etanercept biosimilars market in 2024. The regions covered in the adalimumab, infliximab, and etanercept biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Browse Through More Similar Reports By The Business Research Company:
Oncology Biosimilars Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report
Generic Pharmaceuticals Global Market Opportunities And Strategies To 2033
https://www.thebusinessresearchcompany.com/report/generic-pharmaceuticals-market
Trastuzumab Biosimilars Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/trastuzumab-biosimilar-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
